Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Multiple drugs

Diarrhoea, rash and paronychia (first report with furmonertinib) and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is: First published case report
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Han H, et al. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain alphac-helix: Two case reports and a literature review. Medicine 102: E36667, No. 52, Dec 2023. Available from: URL: https://dx.doi.org/10.1097/MD.0000000000036667 Han H, et al. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain alphac-helix: Two case reports and a literature review. Medicine 102: E36667, No. 52, Dec 2023. Available from: URL: https://​dx.​doi.​org/​10.​1097/​MD.​0000000000036667​
Metadaten
Titel
Multiple drugs
Diarrhoea, rash and paronychia (first report with furmonertinib) and lack of efficacy
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53603-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tozinameran

Case report

Polidocanol

Case report

Levodopa

Case report

Sorafenib